Neratinib clinical trials
Also written Nerlynx and HKI-272.
How each study uses neratinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the neratinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 17 Jul 2017 · NERLYNX · NDA 208051 (FDA, Drugs@FDA)
- European Union
- 31 Aug 2018 · Nerlynx · EMEA/H/C/004030 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
75 studies that test it; most in 2009 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 4 |
| 2007 | 3 |
| 2008 | 6 |
| 2009 | 9 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 6 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 36 · Other 40
Puma Biotechnology, Inc. (33) · NSABP Foundation Inc (4) · Convalife (Shanghai) Co., Ltd. (3) · Memorial Sloan Kettering Cancer Center (2) · Virginia Commonwealth University (2) · Dana-Farber Cancer Institute (2) · National Cancer Institute (NCI) (2) · University Health Network, Toronto (2)
Often tested with
Tested in the same studies.
Trastuzumab (4) · Fulvestrant (4) · Niraparib (3) · Capecitabine (3) · Loperamide (2) · Alpelisib (2) · Binimetinib (2) · Olaparib (2)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 1 in phase 3
Studies that test neratinib, phase 3 first.
- Jun 2027Personalized Medicine for Advanced Biliary Cancer PatientsPhase 3 · UNICANCER
- Dec 2026Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersPhase 2 · Ruth O'Regan
- Jun 2027Neratinib in Combination With Ruxolitinib in Patients With mTNBCEarly Phase 1 · Baylor Research Institute
- Jul 2027Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual DiseasePhase 2 · University Health Network, Toronto
- Oct 2027Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentPhase 1/2 · Memorial Sloan Kettering Cancer Center
- Nov 2027Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerPhase 2 · Xijing Hospital
Studies
Open first, then newest update. How each study uses neratinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 76
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 GeneRecruitingPhase 1National Cancer Institute (NCI)NCT05372614Written as Neratinib Maleate
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05564377Written as Neratinib Maleate
- Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)RecruitingPhase 2Scott R. Plotkin, MD, PhDNCT04374305Written as Neratinib
- Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual DiseaseRecruitingPhase 2University Health Network, TorontoNCT05388149Written as Neratinib
- Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingEarly Phase 1Baylor Research InstituteNCT06008275Written as Neratinib Oral Tablet
- T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisRecruitingPhase 2Fudan UniversityNCT07152782Written as Neratinib
- Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersRecruitingPhase 2Ruth O'ReganNCT04886531Written as Neratinib
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)RecruitingPhase 2David Reardon, MDNCT02977780Written as Neratinib
- Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNot yet recruitingPhase 2University of California, San DiegoNCT07729046Written as Neratinib + endocrine therapy
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Neratinib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Neratinib
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as Neratinib
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 InhibitorRecruitingPhase 2Dartmouth-Hitchcock Medical CenterNCT05933395Written as Neratinib
- Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerNot yet recruitingPhase 2Xijing HospitalNCT07333937Written as Neratinib Combined with Fulvestrant and Eribulin
- Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05760612Written as Trastuzumab and neratinib
- Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 MutationsNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT06519110Written as Neratinib tablets
- Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain MetastasesNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT06374888Written as Neratinib maleate in combination with capecitabine
- Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR MutationsNot yet recruitingPhase 2Convalife (Shanghai) Co., Ltd.NCT06029816Written as Neratinib tablets
- Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to TreatmentActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT02932280Written as Neratinib
- Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated CaSuspendedPhase 1/2Virginia Commonwealth UniversityNCT03919292Written as Neratinib
See all 76 studies that test neratinib →
Given beside what is tested · 6 — neratinib is usual care or a partner of the new treatment
- Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)RecruitingPhase 2National Cancer Institute (NCI)NCT06126276Written as Neratinib Maleate
- Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast CancersRecruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT05919108Written as Neratinib
- Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedPhase 1M.D. Anderson Cancer CenterNCT03065387Written as Neratinib
- Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT03101748Written as Neratinib
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524Written as Neratinib
- Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 StatusStatus unknownPhase 2NSABP Foundation IncNCT03457896Written as Neratinib
Codes
What other systems call neratinib · ClinicalTrials.gg INT004670
- MeSH (NLM) C487932neratinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) JJH94R3PWBNERATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1940643Confirmed FDA, Wikidata
- Wikidata Q6995920neratinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C49094NeratinibConfirmed FDA, Wikidata
- DrugBank DB11828One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C487932 | neratinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | JJH94R3PWB | NERATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1940643 | — | Confirmed FDA, Wikidata |
| Wikidata | Q6995920 | neratinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C49094 | Neratinib | Confirmed FDA, Wikidata |
| DrugBank | DB11828 | — | One source Wikidata |
Also registered as neratinib maleate anhydrous (UNII 9RM7XY23ZS · RxNorm 1940642).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.